Chemicals - Specialty
Compare Stocks
3 / 10Stock Comparison
OEC vs CBT vs KRO
Revenue, margins, valuation, and 5-year total return — side by side.
Chemicals - Specialty
Chemicals - Specialty
OEC vs CBT vs KRO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||
|---|---|---|---|
| Industry | Chemicals - Specialty | Chemicals - Specialty | Chemicals - Specialty |
| Market Cap | $461M | $4.30B | $871M |
| Revenue (TTM) | $1.79B | $3.58B | $1.88B |
| Net Income (TTM) | $-89M | $285M | $-134M |
| Gross Margin | 19.1% | 24.8% | 10.1% |
| Operating Margin | 4.5% | 15.7% | -3.1% |
| Forward P/E | 36.4x | 13.2x | — |
| Total Debt | $980M | $1.22B | $577M |
| Cash & Equiv. | $61M | $258M | $37M |
OEC vs CBT vs KRO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Orion Engineered Ca… (OEC) | 100 | 74.1 | -25.9% |
| Cabot Corporation (CBT) | 100 | 230.7 | +130.7% |
| Kronos Worldwide, I… (KRO) | 100 | 77.6 | -22.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OEC vs CBT vs KRO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
OEC plays a supporting role in this comparison — it may shine differently against other peers.
CBT carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 4 yrs, beta 0.78, yield 2.1%
- Lower volatility, beta 0.78, Low D/E 71.3%, current ratio 1.61x
- Beta 0.78, yield 2.1%, current ratio 1.61x
KRO is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth -1.5%, EPS growth -228.0%, 3Y rev CAGR -1.2%
- 121.1% 10Y total return vs CBT's 115.6%
- -1.5% revenue growth vs CBT's -7.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -1.5% revenue growth vs CBT's -7.0% | |
| Value | Better valuation composite | |
| Quality / Margins | 8.0% margin vs KRO's -7.1% | |
| Stability / Safety | Beta 0.78 vs KRO's 1.57, lower leverage | |
| Dividends | 2.1% yield, 4-year raise streak, vs KRO's 2.6% | |
| Momentum (1Y) | +16.2% vs OEC's -27.8% | |
| Efficiency (ROA) | 7.4% ROA vs KRO's -9.4%, ROIC 17.4% vs -1.9% |
OEC vs CBT vs KRO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
OEC vs CBT vs KRO — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
CBT leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CBT is the larger business by revenue, generating $3.6B annually — 2.0x OEC's $1.8B. CBT is the more profitable business, keeping 8.0% of every revenue dollar as net income compared to KRO's -7.1%. On growth, KRO holds the edge at +4.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||
|---|---|---|---|
| RevenueTrailing 12 months | $1.8B | $3.6B | $1.9B |
| EBITDAEarnings before interest/tax | $180M | $731M | -$9M |
| Net IncomeAfter-tax profit | -$89M | $285M | -$134M |
| Free Cash FlowCash after capex | $68M | $459M | $35M |
| Gross MarginGross profit ÷ Revenue | +19.1% | +24.8% | +10.1% |
| Operating MarginEBIT ÷ Revenue | +4.5% | +15.7% | -3.1% |
| Net MarginNet income ÷ Revenue | -5.0% | +8.0% | -7.1% |
| FCF MarginFCF ÷ Revenue | +3.8% | +12.8% | +1.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -3.8% | -3.4% | +4.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.1% | -23.1% | -126.1% |
Valuation Metrics
OEC leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, OEC's 5.9x EV/EBITDA is more attractive than KRO's 42.5x.
| Metric | |||
|---|---|---|---|
| Market CapShares × price | $461M | $4.3B | $871M |
| Enterprise ValueMkt cap + debt − cash | $1.4B | $5.3B | $1.4B |
| Trailing P/EPrice ÷ TTM EPS | -6.61x | 13.69x | -7.89x |
| Forward P/EPrice ÷ next-FY EPS est. | 36.36x | 13.23x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — |
| EV / EBITDAEnterprise value multiple | 5.91x | 6.79x | 42.51x |
| Price / SalesMarket cap ÷ Revenue | 0.26x | 1.16x | 0.47x |
| Price / BookPrice ÷ Book value/share | 1.20x | 2.62x | 1.16x |
| Price / FCFMarket cap ÷ FCF | 9.19x | 11.01x | — |
Profitability & Efficiency
CBT leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
CBT delivers a 16.8% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-22 for OEC. CBT carries lower financial leverage with a 0.71x debt-to-equity ratio, signaling a more conservative balance sheet compared to OEC's 2.55x. On the Piotroski fundamental quality scale (0–9), CBT scores 6/9 vs OEC's 4/9, reflecting solid financial health.
| Metric | |||
|---|---|---|---|
| ROE (TTM)Return on equity | -21.8% | +16.8% | -17.0% |
| ROA (TTM)Return on assets | -4.6% | +7.4% | -9.4% |
| ROICReturn on invested capital | +5.5% | +17.4% | -1.9% |
| ROCEReturn on capital employed | +7.8% | +21.3% | -2.2% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 | 5 |
| Debt / EquityFinancial leverage | 2.55x | 0.71x | 0.77x |
| Net DebtTotal debt minus cash | $919M | $957M | $540M |
| Cash & Equiv.Liquid assets | $61M | $258M | $37M |
| Total DebtShort + long-term debt | $980M | $1.2B | $577M |
| Interest CoverageEBIT ÷ Interest expense | -0.14x | 14.72x | -2.32x |
Total Returns (Dividends Reinvested)
CBT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CBT five years ago would be worth $14,375 today (with dividends reinvested), compared to $3,861 for OEC. Over the past 12 months, CBT leads with a +16.2% total return vs OEC's -27.8%. The 3-year compound annual growth rate (CAGR) favors CBT at 7.5% vs OEC's -29.3% — a key indicator of consistent wealth creation.
| Metric | |||
|---|---|---|---|
| YTD ReturnYear-to-date | +56.3% | +23.6% | +70.1% |
| 1-Year ReturnPast 12 months | -27.8% | +16.2% | +4.3% |
| 3-Year ReturnCumulative with dividends | -64.7% | +24.1% | +5.5% |
| 5-Year ReturnCumulative with dividends | -61.4% | +43.8% | -40.9% |
| 10-Year ReturnCumulative with dividends | -23.8% | +115.6% | +121.1% |
| CAGR (3Y)Annualised 3-year return | -29.3% | +7.5% | +1.8% |
Risk & Volatility
CBT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CBT is the less volatile stock with a 0.78 beta — it tends to amplify market swings less than KRO's 1.57 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CBT currently trades 97.4% from its 52-week high vs OEC's 67.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.39x | 0.78x | 1.57x |
| 52-Week HighHighest price in past year | $12.10 | $84.60 | $7.90 |
| 52-Week LowLowest price in past year | $4.35 | $58.33 | $4.08 |
| % of 52W HighCurrent price vs 52-week peak | +67.8% | +97.4% | +95.8% |
| RSI (14)Momentum oscillator 0–100 | 78.0 | 63.9 | 69.2 |
| Avg Volume (50D)Average daily shares traded | 612K | 371K | 343K |
Analyst Outlook
Evenly matched — CBT and KRO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: OEC as "Buy", CBT as "Buy", KRO as "Hold". Consensus price targets imply -5.4% upside for CBT (target: $78) vs -33.9% for KRO (target: $5). For income investors, KRO offers the higher dividend yield at 2.64% vs OEC's 1.02%.
| Metric | |||
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $5.88 | $78.00 | $5.00 |
| # AnalystsCovering analysts | 14 | 15 | 7 |
| Dividend YieldAnnual dividend ÷ price | +1.0% | +2.1% | +2.6% |
| Dividend StreakConsecutive years of raises | 3 | 4 | 0 |
| Dividend / ShareAnnual DPS | $0.08 | $1.77 | $0.20 |
| Buyback YieldShare repurchases ÷ mkt cap | +5.4% | +3.9% | 0.0% |
CBT leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). OEC leads in 1 (Valuation Metrics). 1 tied.
OEC vs CBT vs KRO: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is OEC or CBT or KRO a better buy right now?
For growth investors, Kronos Worldwide, Inc.
(KRO) is the stronger pick with -1. 5% revenue growth year-over-year, versus -7. 0% for Cabot Corporation (CBT). Cabot Corporation (CBT) offers the better valuation at 13. 7x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate Orion Engineered Carbons S. A. (OEC) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — OEC or CBT or KRO?
On forward P/E, Cabot Corporation is actually cheaper at 13.
2x.
03Which is the better long-term investment — OEC or CBT or KRO?
Over the past 5 years, Cabot Corporation (CBT) delivered a total return of +43.
8%, compared to -61. 4% for Orion Engineered Carbons S. A. (OEC). Over 10 years, the gap is even starker: KRO returned +121. 1% versus OEC's -23. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — OEC or CBT or KRO?
By beta (market sensitivity over 5 years), Cabot Corporation (CBT) is the lower-risk stock at 0.
78β versus Kronos Worldwide, Inc. 's 1. 57β — meaning KRO is approximately 101% more volatile than CBT relative to the S&P 500. On balance sheet safety, Cabot Corporation (CBT) carries a lower debt/equity ratio of 71% versus 3% for Orion Engineered Carbons S. A. — giving it more financial flexibility in a downturn.
05Which is growing faster — OEC or CBT or KRO?
By revenue growth (latest reported year), Kronos Worldwide, Inc.
(KRO) is pulling ahead at -1. 5% versus -7. 0% for Cabot Corporation (CBT). On earnings-per-share growth, the picture is similar: Cabot Corporation grew EPS -10. 4% year-over-year, compared to -263. 2% for Orion Engineered Carbons S. A.. Over a 3-year CAGR, KRO leads at -1. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — OEC or CBT or KRO?
Cabot Corporation (CBT) is the more profitable company, earning 8.
9% net margin versus -6. 0% for Kronos Worldwide, Inc. — meaning it keeps 8. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CBT leads at 16. 7% versus -1. 7% for KRO. At the gross margin level — before operating expenses — CBT leads at 25. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is OEC or CBT or KRO more undervalued right now?
On forward earnings alone, Cabot Corporation (CBT) trades at 13.
2x forward P/E versus 36. 4x for Orion Engineered Carbons S. A. — 23. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CBT: -5. 4% to $78. 00.
08Which pays a better dividend — OEC or CBT or KRO?
All stocks in this comparison pay dividends.
Kronos Worldwide, Inc. (KRO) offers the highest yield at 2. 6%, versus 1. 0% for Orion Engineered Carbons S. A. (OEC).
09Is OEC or CBT or KRO better for a retirement portfolio?
For long-horizon retirement investors, Cabot Corporation (CBT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
78), 2. 1% yield, +115. 6% 10Y return). Kronos Worldwide, Inc. (KRO) carries a higher beta of 1. 57 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CBT: +115. 6%, KRO: +121. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between OEC and CBT and KRO?
Both stocks operate in the Basic Materials sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: OEC is a small-cap quality compounder stock; CBT is a small-cap deep-value stock; KRO is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.